Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compass Pathways plc (Nasdaq: CMPS) SEC filings page provides access to the company’s regulatory disclosures as it develops COMP360, an investigational synthetic psilocybin treatment for serious mental health conditions. As a foreign private issuer incorporated in England and Wales and listed on the Nasdaq Global Select Market, Compass reports key information to the U.S. Securities and Exchange Commission through forms such as Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q.
Current reports on Form 8-K for CMPS include items on financial results, clinical milestones, and corporate governance. For example, Compass has filed 8-Ks to furnish press releases announcing financial results for periods ended June 30 and September 30, 2025, and to report board changes such as the appointments of new directors and related compensation arrangements. Other 8-K filings describe clinical developments, including achievement of the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant depression.
Investors can also use this page to track periodic reports (10-K and 10-Q), which contain detailed discussions of Compass Pathways’ business, risk factors, clinical programs for treatment-resistant depression and post-traumatic stress disorder, and financial statements. These documents elaborate on topics such as research and development spending, funding needs, and the risks inherent in clinical development and regulatory review of COMP360.
In addition, this filings page can surface governance and compensation disclosures, including information about director appointments, option grants under the company’s share option and incentive plan, and indemnity arrangements, as reflected in specific 8-K items. Real-time updates from EDGAR combined with AI-powered summaries can help readers quickly understand the key points of lengthy filings, from clinical data descriptions to financial condition discussions, without reading every page of the underlying documents.
COMPASS Pathways plc reported that Chief Executive Officer Kabir Nath received new equity-based compensation. He was granted options to purchase 367,815 Ordinary Shares at an exercise price of $5.64 per share, vesting in forty-eight equal monthly installments beginning on April 26, 2026.
He was also granted 175,000 Ordinary Shares in the form of Restricted Share Units under the 2020 Share Option and Incentive Plan. These RSUs vest in four equal annual installments, with the first installment vesting on March 26, 2027. Following the RSU grant, he directly holds 366,990 Ordinary Shares.
Compass Pathways plc reported that Chief Medical Officer Guy Goodwin received two new stock option awards. He was granted options over 55,000 ordinary shares at an exercise price of 0.01 per share and options over 115,600 ordinary shares at an exercise price of 5.64 per share.
The 55,000-share nominal cost option vests in four equal annual installments beginning on March 26, 2027. The 115,600-share option vests in 48 equal monthly installments beginning on April 26, 2026. Each ordinary share may be represented by one American Depositary Share. No open-market purchases or sales were reported in this filing.
Compass Pathways plc Chief Financial Officer Teri Loxam received new equity awards as part of compensation. She was granted share options covering 157,635 Ordinary Shares at an exercise price of $5.64 per share, expiring on March 25, 2036. These options vest in forty-eight equal monthly installments beginning on April 26, 2026.
She also received 75,000 Restricted Share Units (RSUs), each representing one Ordinary Share, with vesting in four equal annual installments starting on March 26, 2027. Following this RSU grant, she directly owns 152,002 Ordinary Shares. The company notes that Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Compass Pathways is a clinical-stage biotech focused on its investigational COMP360 psilocybin treatment for serious mental health conditions, primarily treatment‑resistant depression (TRD) and PTSD. The company completed enrollment in two Phase 3 TRD trials and reported that both achieved their primary endpoints on the MADRS depression scale.
In COMP005, a single 25 mg dose of COMP360 showed a highly statistically significant and clinically meaningful MADRS improvement versus placebo at week 6, with durable effects through 26 weeks after one or two doses. In COMP006, two 25 mg doses given three weeks apart outperformed 1 mg on MADRS at week 6, also with rapid onset. COMP360 has generally shown a tolerable safety profile, with most adverse events mild or moderate and resolving within a day.
Based on these data, Compass plans to complete a rolling NDA submission for TRD in the fourth quarter of 2026 and is accelerating U.S. launch planning. The FDA has also accepted an IND for a Phase 2b/3 PTSD trial after an open‑label Phase 2 study showed large, durable reductions in CAPS‑5 PTSD severity and functional impairment.
Compass Pathways reported a much larger full-year 2025 net loss of $287.9 million (vs. $155.1 million in 2024), driven mainly by a $122.6 million non-cash fair value loss on warrant liabilities. Operating expenses were broadly flat, with R&D at $118.4 million and G&A at $60.6 million.
Cash and cash equivalents were $149.6 million at December 31, 2025, with debt of $31.6 million at that date (and $50.4 million by March 24, 2026). After a $150 million financing and $200 million warrant exercises, the company expects its cash position as of March 24, 2026 to fund operations into 2028.
Clinically, COMP360 achieved positive Phase 3 results in treatment‑resistant depression across large trials, showing rapid and durable responses with a generally well-tolerated safety profile. Compass plans a rolling NDA submission with completion expected in Q4 2026, aims to be launch-ready by the end of 2026, and is initiating a Phase 2b/3 PTSD trial following FDA IND acceptance.
COMPASS Pathways plc reported a routine insider tax-related transaction by its Chief Executive Officer, Kabir Nath. On March 11, 2026, 13,131 Ordinary Shares were disposed of at $6.89 per share, but this was a tax-withholding disposition rather than an open-market sale. The shares were withheld by the company upon the vesting of restricted share units to cover tax obligations, so the CEO did not actively trade these shares in the market. Following this event, Nath directly owned 191,990 Ordinary Shares. Each Ordinary Share may be represented by an American Depositary Share on the U.S. market.
COMPASS Pathways plc Chief Financial Officer Teri Loxam reported a routine tax-related share disposition. On the vesting of restricted share units, 1,781 Ordinary Shares were withheld by the company at a value of $6.89 per share to satisfy tax withholding obligations. After this withholding, Loxam directly owns 77,002 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
COMPASS Pathways plc Chief Financial Officer Teri Loxam reported a tax-related share disposition. On the transaction date, 4,467 Ordinary Shares were withheld by the company upon vesting of restricted share units to satisfy tax withholding obligations. After this withholding, Loxam directly owned 78,783 Ordinary Shares.
Compass Pathways plc is raising new equity capital through an underwritten public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 per ADS and pre-funded warrants to purchase up to 1,250,000 ADSs at $7.999 per warrant. Underwriters also have a 30‑day option to buy up to 2,812,500 additional ADSs. Gross proceeds are expected to be $150.0 million before fees and expenses. All securities are being sold by the company, with closing expected around February 20, 2026, subject to customary conditions.
The pre-funded warrants carry a nominal exercise price of $0.0001 per ADS, are exercisable immediately, and include a Beneficial Ownership Limitation generally capped at 9.99%, which holders can adjust up to 19.99% with notice. The company, its officers and directors have agreed to a 60‑day lock-up on additional sales.
Compass Pathways intends to use net proceeds, together with existing cash, to fund its COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 COMP360 PTSD program, accelerate commercial readiness activities, and for working capital and general corporate purposes.
COMPASS Pathways plc is offering 17,500,000 American Depositary Shares and pre-funded warrants to purchase 1,250,000 ADSs. The ADSs are being sold at $8.00 per ADS and the pre-funded warrants at $7.9999 each, with aggregate public offering proceeds shown as $149,999,875 and estimated net proceeds of approximately $140.5 million after underwriting discounts and estimated offering expenses.
The offering includes a 30-day underwriters' option to purchase up to 2,812,500 additional ADSs. The company intends to use net proceeds to fund its ongoing COMP005 and COMP006 Phase 3 trials for treatment-resistant depression, a Phase 2b/3 trial in PTSD, accelerate commercial readiness activities, and for working capital and general corporate purposes.